Abstract
Objective
Community acquired pneumonia (CAP) is the most important clinical infection. Therefore, the CAP competence network CAPNETZ was instituted in Germany. The aim of this substudy was to evaluate the value of pro-atrial natriuretic peptide (MR-proANP) and pro-vasopressin (CT-proAVP) for severity assessment and outcome prediction in CAP.
Design
Prospective observational study.
Setting
German CAP competence network CAPNETZ.
Methods
We enrolled 589 patients (age 61 ± 18 years, 46% female) with proven CAP. MR-proANP, CT-proAVP, C-reactive protein (CRP), procalcitonin (PCT) and CRB-65 score were determined on admission.
Results
MR-proANP, CT-proAVP and PCT levels, but not CRP, increased with increasing severity of CAP, classified according to the CRB-65 score. In patients who died during 28-day follow-up, median MR-proANP and CT-proAVP levels (respectively 237.0 vs. 93.5 pmol/l and 44.2 vs. 12.4 pmol/l, each p < 0.0001) were significantly higher than in survivors. In receiver operating characteristic (ROC) analysis for survival, the area under the curve (AUC) values for CT-proAVP (0.86, 95% CI 0.83–0.89) and MR-proANP (0.76, 95% CI 0.72–0.80) were similar to the AUC of CRB-65 (0.73, 95% CI 0.70–0.77). In multivariable Cox proportional-hazards regression analyses including MR-proANP/CT-proAVP, coexisting illnesses and CRB-65, increased MR-proANP and CT-proAVP concentrations were the strongest predictors of mortality.
Conclusions
MR-proANP and CT-proAVP are useful new biomarkers for the risk stratification of CAP patients. They are significantly lower in CAP survivors and correlate with the severity of the disease measured by CRB-65 score.
Similar content being viewed by others
References
Welte T, Suttorp N, Marre R (2004) CAPNETZ-community-acquired pneumonia competence network. Infection 32:234–238
Almirall J, Bolibar I, Vidal J, Sauca G, Coll P, Niklasson B, Bartolome M, Balanzo X (2000) Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 15:757–763
Baik I, Curhan GC, Rimm EB, Bendich A, Willett WC, Fawzi WW (2000) A prospective study of age and lifestyle factors in relation to community-acquired pneumonia in US men and women. Arch Intern Med 160:3082–3088
Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, Chambers ST, Town GI (1996) Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 51:1010–1016
Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250
Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382
Capelastegui A, Espana PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, Bilbao A (2006) Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 27:151–157
Ewig S, Torres A, Woodhead M (2006) Assessment of pneumonia severity: a European perspective. Eur Respir J 27:6–8
Niederman MS, Feldmann C, Richards GA (2006) Combining information from prognostic scoring tools for CAP: an American view on how to get the best of all worlds. Eur Respir J 27:9–11
Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV (2006) A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 61:419–424
Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society (2001) Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163:1730–1754
Bauer TT, Ewig S, Marre R, Suttorp N, Welte T, the Capnetz Study Group (2006) CRB-65 predicts death from community-acquired pneumonia. J Intern Med 260:93–101
Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, Saltzberg M, Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R, Rapid Emergency Department Heart Failure Outpatient Trial investigators (2004) Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44:1328–1333
Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161–167
Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiss C, Kaden JJ, Putensen C, Borggrefe M, Hoffmann U (2005) Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112:527–534
Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, Stuttmann R, Speichermann N, Verner L, Werdan K (2003) Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 29:1696–1702
Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Müller B (2003) Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Critical Care 9:R37–R45
Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schwarz S, Hasibeder WR, Friesenecker BE, Dunser MW (2006) Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 91:4381–4286
Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, Knotzer H, Pajk W, Hasibeder W, Friesenecker B, Mayr AJ, Dunser MW (2006) Serum vasopressin concentrations in critically ill patients. Crit Care Med 34:293–299
Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119
Struck J, Morgenthaler NG, Bergmann A (2005) Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 26:2500–2504
Morgenthaler NG, Struck J, Thomas B, Bergmann A (2004) Immunoluminometric aasay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 50:234–236
Mauch H, Marklein G, Kühnen E (2000) Infektionen der tiefen Atemwege. In: Mauch H., Lütticken R, Gatermann S. Quality standards for microbiological diagnostic techniques for infectious diseases. Urban & Fischer, Munich
Mueller C, Laule-Kilian K, Scholer A, Perruchoud AP (2005) B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 258:391–393
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130
Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A (2001) A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37:386–391
Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS (2001) Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent care setting. J Am Coll Cardiol 37:379–385
Krüger S, Graf J, Kunz D, Stickel T, Hanrath P, Janssens U (2002) Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 40:718–722
Tillett WS, Francis T Jr (1930) Serological reactions in pneumonia with non-protein somatic fraction of pneumococcus. J Exp Med 52:561–571
Ortqvist A, Hedlund J, Wretlind B, Carlstrom A, Kalin M (1995) Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 27:457–462
Garcia Vazquez E, Martinez JA, Mensa J, Sanchez F, Marcos MA, de Roux A, Torres A (2003) C-reactive protein levels in community-acquired pneumonia. Eur Respir J 21:702–705
Hedlund J, Hansson LO (2000) Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 28:68–73
Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B (2002) Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis 34:895–901
Masia M, Gutierrez F, Shum C, Padilla S, Navarro JC, Flores E, Hernandez I (2005) Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index. Chest 128:2223–2229
Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, Arndt G, Lode H (2003) Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 21:939–943
Boussekey N, Leroy O, Alfandari S, Devos P, Georges H, Guery B (2006) Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 32:469–472
McLean AS, Huang SJ, Nalos M, Tang B, Stewart DE (2003) The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med 31:2611–2618
Acknowledgements
This study was supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF), grants 01KI0103-105, Competence Network CAPNETZ. The authors are grateful to their fellow members of the CAPNETZ Study Group and to all study nurses. Furthermore, the authors wish to thank Angelina Herzberg, Johanna Hetzel, Barbara Schäffus, and Anne Schmiedel for excellent technical assistance.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Contributors: Stefan Krüger and Jana Papassotiriou helped to plan the study, performed data processing and interpretation and wrote the manuscript. Nils Morgenthaler helped to plan the study and interpret the results. Norbert Suttorp, Reinhard Marre and Tobias Welte organised CAPNETZ and data processing, planned the study and helped with the manuscript. Klaus Richter was involved in planning the study and statistical analysis. Christian Schumann helped in data processing and patient recruitment. Heike von Baum organised microbiological work in the central study unit.
Conflict of interest: Jana Papassotiriou and Nils Morgenthaler are employees of Brahms AG, the manufacturer of the assays Brahms MR-proANP LIA and Brahms CT-proAVP LIA (Hennigsdorf, Germany).
This article is discussed in the editorial available at: http://dx.doi.org/10.1007/s00134-007-0896-4.
Electronic supplementary material
Members of CAPNETZ Study Group
Members of CAPNETZ Study Group
Markus Becker, Antje Kuhnke, Hartmut Lode, Malina Schmidt-Ioanas, Norbert Suttorp, (Berlin); Torsten Bauer, Santiago Ewig, Barbara Schlosser (Bochum); Matthias Pletz, Tobias Welte (Hannover); Klaus Dalhoff, Sven Pischke, Niels Schübel (Lübeck); Ingrid Huntemann, Joachim Lorenz (Lüdenscheid); Thomas Klante (Magdeburg); Tom Schaberg, Konstanze Voigt (Rotenburg); Stefan Krüger, Christian Schumann (Ulm); Berthold Jany, Uwe Ziegler (Würzburg); Torsten Illmann, Michael Wallner, Michael Weber (IT); Heike von Baum, Susanne Gonschior, Klaus Richter (main office).
Rights and permissions
About this article
Cite this article
Krüger, S., Papassotiriou, J., Marre, R. et al. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia. Intensive Care Med 33, 2069–2078 (2007). https://doi.org/10.1007/s00134-007-0895-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-007-0895-5